| Literature DB >> 33441539 |
Chandrakanta S Hiremath1, Kommu John Vijay Sagar2, B K Yamini3, Akhila S Girimaji3, Raghavendra Kumar2, Sanivarapu Lakshmi Sravanti2, Hansashree Padmanabha4, K N Vykunta Raju5, M Thomas Kishore6, Preeti Jacob2, Jitender Saini1, Rose D Bharath1, Shekhar P Seshadri2, Manoj Kumar7.
Abstract
The possibility of early treatment and a better outcome is the direct product of early identification and characterization of any pathological condition. Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairment in social communication, restricted, and repetitive patterns of behavior. In recent times, various tools and methods have been developed for the early identification and characterization of ASD features as early as 6 months of age. Thorough and exhaustive research has been done to identify biomarkers in ASD using noninvasive neuroimaging and various molecular methods. By employing advanced assessment tools such as MRI and behavioral assessment methods for accurate characterization of the ASD features and may facilitate pre-emptive interventional and targeted therapy programs. However, the application of advanced quantitative MRI methods is still confined to investigational/laboratory settings, and the clinical implication of these imaging methods in personalized medicine is still in infancy. Longitudinal research studies in neurodevelopmental disorders are the need of the hour for accurate characterization of brain-behavioral changes that could be monitored over a period of time. These findings would be more reliable and consistent with translating into the clinics. This review article aims to focus on the recent advancement of early biomarkers for the characterization of ASD features at a younger age using behavioral and quantitative MRI methods.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33441539 PMCID： PMC7806884 DOI： 10.1038/s41398-020-01178-6
Source DB: PubMed Journal: Transl Psychiatry ISSN： 2158-3188 Impact factor: 6.222